1. evolving challenges confronting adults living with HIV in three North African countries during the COVID-19 crisis: a survey-based study.
- Author
-
Cordie, Ahmed, AbdAllah, Mohamed, Desouky, Eman El, Kheir, Sara Gabrallah Mohamed, Kooli, Ikbal, Mousnad, Mohamed Awad, Idris, Fatima Haj, Abdella, Heba, Chakroun, Mohamed, and Esmat, Gamal
- Subjects
COVID-19 pandemic ,COVID-19 ,INFLUENZA ,HIV protease inhibitors ,HIV ,COUGH ,HIV-positive persons - Abstract
Background Coronavirus disease 2019 (COVID-19) has resulted in a huge burden on healthcare systems, especially on programs for chronic illnesses such as HIV. We aimed to assess the challenges confronting adult people living with HIV (PLHIV) in three countries in North Africa during the COVID-19 crisis and their awareness of COVID-19 non-pharmaceutical preventive measures. Methods This online survey included PLHIV aged ≥18 y from three countries in North Africa recruited by a snowball sampling technique, who were asked to complete a modified questionnaire originally developed by the University of Antwerp in Belgium, which was then disseminated through social media tools to assess the study outcomes. Results Out of 369 respondents, 260 (70.5%) were males and 237 (64.2%) were aged 18–39 y. Adherence to COVID-19 preventive measures, wearing facemasks (308 [83.2%]), applying hand-sanitizers (299 [80.8%]) and following cough etiquette (261 [70.5%]), were predominantly reported. Only 48 (13%) were vaccinated against influenza. One hundred and forty-five participants (42%) experienced flu-like symptoms, 29 (20%) were tested for COVID-19, with only one confirmed case identified. Among 344 (93.2%) on antiretroviral therapy (73.8% efavirenz- vs 6.4% dolutegravir-based regimens), 219 (63.7%) attended their scheduled visits, 144 (41.9%) had limited access to care due to lockdown and 29 (8.4%) became less adherent to their antiretroviral therapy. Covariates associated with challenges during access to care were age ≥60 y (OR=6.5; 95% CI 1.8 to 23.2) and receiving second-line HIV treatment such as protease inhibitors (OR=2.7; 95% CI 1.3 to 5.8). Conclusion The pandemic adversely affected PLHIV. New innovative strategies should be implemented to ensure the continuity of HIV services. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF